Cargando…

Assessing the Protective Potential of H1N1 Influenza Virus Hemagglutinin Head and Stalk Antibodies in Humans

Seasonal influenza viruses are a major cause of human disease worldwide. Most neutralizing antibodies (Abs) elicited by influenza viruses target the head domain of the hemagglutinin (HA) protein. Anti-HA head Abs can be highly potent, but they have limited breadth since the HA head is variable. Ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Christensen, Shannon R., Toulmin, Sushila A., Griesman, Trevor, Lamerato, Lois E., Petrie, Joshua G., Martin, Emily T., Monto, Arnold S., Hensley, Scott E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450120/
https://www.ncbi.nlm.nih.gov/pubmed/30700610
http://dx.doi.org/10.1128/JVI.02134-18
_version_ 1783408979546734592
author Christensen, Shannon R.
Toulmin, Sushila A.
Griesman, Trevor
Lamerato, Lois E.
Petrie, Joshua G.
Martin, Emily T.
Monto, Arnold S.
Hensley, Scott E.
author_facet Christensen, Shannon R.
Toulmin, Sushila A.
Griesman, Trevor
Lamerato, Lois E.
Petrie, Joshua G.
Martin, Emily T.
Monto, Arnold S.
Hensley, Scott E.
author_sort Christensen, Shannon R.
collection PubMed
description Seasonal influenza viruses are a major cause of human disease worldwide. Most neutralizing antibodies (Abs) elicited by influenza viruses target the head domain of the hemagglutinin (HA) protein. Anti-HA head Abs can be highly potent, but they have limited breadth since the HA head is variable. There is great interest in developing new universal immunization strategies that elicit broadly neutralizing Abs against conserved regions of HA, such as the stalk domain. Although HA stalk Abs can provide protection in animal models, it is unknown if they are present at sufficient levels in humans to provide protection against naturally acquired influenza virus infections. Here, we quantified H1N1 HA head- and stalk-specific Abs in 179 adults hospitalized during the 2015–2016 influenza virus season. We found that HA head Abs, as measured by hemagglutinin inhibition (HAI) assays, were associated with protection against naturally acquired H1N1 infection. HA stalk-specific serum total IgG titers were also associated with protection, but this association was attenuated and not statistically significant after adjustment for HA head-specific Ab titers. We found slightly higher titers of HA stalk-specific IgG1 and IgA Abs in sera from uninfected participants than in sera from infected participants; however, we found no difference in serum in vitro antibody-dependent cellular cytotoxicity activity. In passive transfer experiments, sera from participants with high HAI activity efficiently protected mice, while sera with low HAI activity protected mice to a lower extent. Our data suggest that HA head Abs are more efficient at protecting against H1N1 infection than HA stalk Abs. IMPORTANCE Abs targeting the HA head of influenza viruses are often associated with protection from influenza virus infections. These Abs typically have limited breadth, since mutations frequently arise in HA head epitopes. New vaccines targeting the more conserved HA stalk domain are being developed. Abs that target the HA stalk are protective in animal models, but it is unknown if these Abs exist at protective levels in humans. Here, we completed experiments to determine if Abs against the HA head and stalk were associated with protection from naturally acquired human influenza virus infections during the 2015–2016 influenza season.
format Online
Article
Text
id pubmed-6450120
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-64501202019-04-19 Assessing the Protective Potential of H1N1 Influenza Virus Hemagglutinin Head and Stalk Antibodies in Humans Christensen, Shannon R. Toulmin, Sushila A. Griesman, Trevor Lamerato, Lois E. Petrie, Joshua G. Martin, Emily T. Monto, Arnold S. Hensley, Scott E. J Virol Pathogenesis and Immunity Seasonal influenza viruses are a major cause of human disease worldwide. Most neutralizing antibodies (Abs) elicited by influenza viruses target the head domain of the hemagglutinin (HA) protein. Anti-HA head Abs can be highly potent, but they have limited breadth since the HA head is variable. There is great interest in developing new universal immunization strategies that elicit broadly neutralizing Abs against conserved regions of HA, such as the stalk domain. Although HA stalk Abs can provide protection in animal models, it is unknown if they are present at sufficient levels in humans to provide protection against naturally acquired influenza virus infections. Here, we quantified H1N1 HA head- and stalk-specific Abs in 179 adults hospitalized during the 2015–2016 influenza virus season. We found that HA head Abs, as measured by hemagglutinin inhibition (HAI) assays, were associated with protection against naturally acquired H1N1 infection. HA stalk-specific serum total IgG titers were also associated with protection, but this association was attenuated and not statistically significant after adjustment for HA head-specific Ab titers. We found slightly higher titers of HA stalk-specific IgG1 and IgA Abs in sera from uninfected participants than in sera from infected participants; however, we found no difference in serum in vitro antibody-dependent cellular cytotoxicity activity. In passive transfer experiments, sera from participants with high HAI activity efficiently protected mice, while sera with low HAI activity protected mice to a lower extent. Our data suggest that HA head Abs are more efficient at protecting against H1N1 infection than HA stalk Abs. IMPORTANCE Abs targeting the HA head of influenza viruses are often associated with protection from influenza virus infections. These Abs typically have limited breadth, since mutations frequently arise in HA head epitopes. New vaccines targeting the more conserved HA stalk domain are being developed. Abs that target the HA stalk are protective in animal models, but it is unknown if these Abs exist at protective levels in humans. Here, we completed experiments to determine if Abs against the HA head and stalk were associated with protection from naturally acquired human influenza virus infections during the 2015–2016 influenza season. American Society for Microbiology 2019-04-03 /pmc/articles/PMC6450120/ /pubmed/30700610 http://dx.doi.org/10.1128/JVI.02134-18 Text en Copyright © 2019 Christensen et al. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Pathogenesis and Immunity
Christensen, Shannon R.
Toulmin, Sushila A.
Griesman, Trevor
Lamerato, Lois E.
Petrie, Joshua G.
Martin, Emily T.
Monto, Arnold S.
Hensley, Scott E.
Assessing the Protective Potential of H1N1 Influenza Virus Hemagglutinin Head and Stalk Antibodies in Humans
title Assessing the Protective Potential of H1N1 Influenza Virus Hemagglutinin Head and Stalk Antibodies in Humans
title_full Assessing the Protective Potential of H1N1 Influenza Virus Hemagglutinin Head and Stalk Antibodies in Humans
title_fullStr Assessing the Protective Potential of H1N1 Influenza Virus Hemagglutinin Head and Stalk Antibodies in Humans
title_full_unstemmed Assessing the Protective Potential of H1N1 Influenza Virus Hemagglutinin Head and Stalk Antibodies in Humans
title_short Assessing the Protective Potential of H1N1 Influenza Virus Hemagglutinin Head and Stalk Antibodies in Humans
title_sort assessing the protective potential of h1n1 influenza virus hemagglutinin head and stalk antibodies in humans
topic Pathogenesis and Immunity
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450120/
https://www.ncbi.nlm.nih.gov/pubmed/30700610
http://dx.doi.org/10.1128/JVI.02134-18
work_keys_str_mv AT christensenshannonr assessingtheprotectivepotentialofh1n1influenzavirushemagglutininheadandstalkantibodiesinhumans
AT toulminsushilaa assessingtheprotectivepotentialofh1n1influenzavirushemagglutininheadandstalkantibodiesinhumans
AT griesmantrevor assessingtheprotectivepotentialofh1n1influenzavirushemagglutininheadandstalkantibodiesinhumans
AT lameratoloise assessingtheprotectivepotentialofh1n1influenzavirushemagglutininheadandstalkantibodiesinhumans
AT petriejoshuag assessingtheprotectivepotentialofh1n1influenzavirushemagglutininheadandstalkantibodiesinhumans
AT martinemilyt assessingtheprotectivepotentialofh1n1influenzavirushemagglutininheadandstalkantibodiesinhumans
AT montoarnolds assessingtheprotectivepotentialofh1n1influenzavirushemagglutininheadandstalkantibodiesinhumans
AT hensleyscotte assessingtheprotectivepotentialofh1n1influenzavirushemagglutininheadandstalkantibodiesinhumans